SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC

Advanced Nasopharyngeal Carcinoma Clinical Trial

Official title:
Stereotactic Body Radiotherapy (SBRT) Combined With Chemotherapy and Tislelizumab in Metastatic Nasopharyngeal Carcinoma: A Single-arm, Phase Ⅱ Study

Status Recruiting

Clinical Trial Summary

Radiotherapy and immunotherapy have achieved good survival benefit in advanced nasopharyngeal carcinoma. A number of clinical studies of immunotherapy combined with radiotherapy for nasopharyngeal carcinoma are also ongoing. This study preliminarily explored the efficacy and safety of SBRT combined with tislelizumab and chemotherapy in metastatic nasopharyngeal carcinoma. Hypofractionated radiotherapy combine with systemic chemotherapy and immunotherapy in advanced nasopharyngeal carcinoma. Not only it can achieve rapid response of distant metastases, but also to achieve long-term survival benefit for patients, which provides the reference for subsequent studies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Nasopharyngeal Carcinoma
Carcinoma
Nasopharyngeal Carcinoma

Clinical Trial Details

NCT number	NCT05652192
Study type	Interventional
Source	Zhejiang Cancer Hospital
Contact	Feng Jiang, MD
Phone	0086-571-88128202
Email	jiangfeng@zjcc.org.cn
Status	Recruiting
Phase	Phase 2
Start date	September 15, 2022
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05751486` - A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma	Phase 1
Not yet recruiting	`NCT03723343` - GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
Completed	`NCT01365208` - New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer	N/A